CRS 2017: The Role of HDL-C in Cardiovascular Disease

October 21, 2017 at 10:55am

Although HDL cholesterol is consistently associated with higher cardiovascular risk, the targeting of HDL has not meaningfully improved outcomes, according to Amit Khera, MD, MSc, FACC, FAHA, FASPC, who will present further on the subject in “The Role of HDL-C in Cardiovascular Disease.”

Firstly, Khera will discuss the “HDL-C paradox,” and several studies that have detailed the effects of HDL level on risk of cardiovascular disease, as well as the ineffectiveness of HDL cholesterol-raising therapies in decreasing this HDL-related cardiovascular risk.

Next, he will discuss the question of why HDL-raising therapies have been disappointing, and how HDL biology could be more complicated than a “simple number.”

Lastly, Khera will discuss the relationship between cholesterol efflux and cardiovascular events, and the benefits of statin therapy over several HDL cholesterol tertiles.

—Michael Potts

Reference:

Khera A. The Role of HDL-C in cardiovascular disease [presented at Cardiometabolic Risk Summit 2017]. Dallas, Texas. October 21, 2017.